HIV-1 viral decay in blood and semen in antiretroviral-naive adults initiating dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide

被引：0
|
作者：
Wang, Ran [1 ]
Liu, Yongjian [2 ]
Sun, Lijun [1 ]
Li, Aixin [1 ]
Lv, Shiyun [1 ]
Zhai, Yuanyi [1 ]
Li, Rui [1 ]
Hua, Wei [1 ]
Wang, Xi [1 ]
Li, Lin [2 ]
Dai, Lilli [1 ]
机构：
[1] Capital Med Univ, Beijing Youan Hosp, Ctr Infect Dis, Beijing, Peoples R China
[2] Acad Mil Med Sci, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2024年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P114
引用
收藏
页码：121 / 121
页数：1
相关论文
共 50 条
  • [21] Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
    Podzamczer, D.
    Mican, R.
    Tiraboschi, J.
    Portilla, J.
    Domingo, P.
    Llibre, J. M.
    Ribera, E.
    Vivancos, M. J.
    Morano, L.
    Masia, M.
    Gomez, C.
    Fanjul, F.
    Payeras, A.
    Inciarte, A.
    Estrada, V
    Rivero, A.
    Castro, A.
    Bernal, E.
    Vinuesa, D.
    Knobel, H.
    Troya, J.
    Macias, J.
    Montero, M.
    Sanz, J.
    Navarro-Alcaraz, A.
    Caicedo, A.
    Fernandez, G.
    Martinez, E.
    Moreno, S.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (03):
  • [22] Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data: Erratum
    D'Antoni, Michelle L.
    Andreatta, Kristen
    Chang, Silvia
    Cox, Stephanie
    Hindman, Jason T.
    Avihingsanon, Anchalee
    Martin, Hal
    VanderVeen, Laurie A.
    Callebaut, Christian
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 97 (02) : 202 - 202
  • [23] Effectiveness, safety and tolerability of dolutegravir/lamivudine versus tenofovir alafenamide/emtricitabine/bictegravir in a real-life cohort of HIV-1 virologically suppressed treatment experienced people living with HIV
    Tordi, S.
    De Socio, G. V.
    Altobelli, D.
    Gidari, A.
    Zoffoli, A.
    Francisci, D.
    HIV MEDICINE, 2023, 24 : 153 - 155
  • [24] Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study
    Rolle, Charlotte-Paige
    Castano, Jamie
    Nguyen, Vu
    Hinestrosa, Federico
    Dejesus, Edwin
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (10):
  • [25] Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
    De Socio, Giuseppe Vittorio
    Tordi, Sara
    Altobelli, Debora
    Gidari, Anna
    Zoffoli, Anastasia
    Francisci, Daniela
    Wozniacka, Anna
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (24)
  • [26] Comparing lamivudine plus dolutegravir and bictegravir/emtricitabine/ tenofovir alafenamide in antiretroviral therapynaive HIV-infected patients: preliminary results from clinical practice
    Long, H.
    HIV MEDICINE, 2023, 24 : 105 - 106
  • [27] Dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate: Real-world Assessment of weight Gain in naive people living with HIV of Asian OrigiN (DRAGON study)
    Chen, Jang-Pin
    Chen, Tsung-Chia
    Hsih, Wen-Hsin
    Tsai, Mao-Song
    Yang, Chia-Jui
    Cheng, Shu-Hsing
    Lin, Yi-Chun
    Ma, Ping
    Zhao, Qingxia
    Zou, Meiyin
    Wu, Yi-Wen
    Huang, Miao-Hui
    Sheng, Wang-Huei
    Cheng, Chien-Yu
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 267 - 268
  • [28] Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
    Januszka, Jenna E.
    Drwiega, Emily N.
    Badowski, Melissa E.
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2023, 15 : 705 - 711
  • [29] 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study
    Moyle, Graeme J.
    Stellbrink, Hans-Juergen
    Compston, Juliet
    Orkin, Chloe
    Arribas, Jose R.
    Domingo, Pere
    Granier, Catherine
    Pearce, Helen
    Sedani, Sangeeta
    Gartland, Martin
    ANTIVIRAL THERAPY, 2013, 18 (07) : 905 - 913
  • [30] Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
    Sax, Paul E.
    DeJesus, Edwin
    Crofoot, Gordon
    Ward, Douglas
    Benson, Paul
    Dretler, Robin
    Mills, Anthony
    Brinson, Cynthia
    Peloquin, Julie
    Wei, Xuelian
    White, Kirsten
    Cheng, Andrew
    Martin, Hal
    Quirk, Erin
    LANCET HIV, 2017, 4 (04): : E154 - E160
12345